Skip to main content

NeuroPace Inc 10-Q for FY2026 Q3

NeuroPace Inc (NPCE)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 12, 2026

About this 10-Q

NeuroPace Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

NeuroPace said the FDA found its PMA-S for drug-resistant idiopathic generalized epilepsy not approvable in its current form. After meeting with the FDA, it is adding NAUTILUS data and context; nine-month revenue rose 11% to $67.9 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$23.1M
down 1.1% from $23.35M a year earlier
Net loss
$3.3M
compared with a net loss of $3.5M a year earlier
Diluted EPS
-$0.10
compared with -$0.11 a year earlier